BIONTECH SE SPON. ADRS 1
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Nico Popp on January 30th, 2026 | 07:25 CET
The hunt for the cancer pill from BioNTech & Co.: Why Eli Lilly's billion-dollar bet is a wake-up call for Vidac Pharma
It is one of the oldest rules in the biotech sector: when the big pharmaceutical companies can no longer grow on their own, they open their coffers. The latest billion-dollar deal between US giant Eli Lilly and Dresden-based startup Seamless Therapeutics is more than just a headline – it is a wake-up call for the entire industry. Eli Lilly, now one of the most valuable companies in the world, is desperately seeking innovations to secure its pipeline beyond its booming weight-loss injections. This hunger for new mechanisms of action inevitably focuses attention on small, specialized companies researching revolutionary approaches. In this environment, Vidac Pharma is becoming the focus of strategic investors. The Company is working on an approach that is as elegant as it is radical: it aims to starve cancer rather than poison it by manipulating its metabolism. While Eli Lilly and BioNTech are spreading their billions across a wide range of areas, Vidac is delivering precisely the kind of specialized "deep science" that is often lacking in the pipelines of the big players.
Read
Commented by Fabian Lorenz on January 26th, 2026 | 01:35 CET
BASF under PRESSURE! BUY RECOMMENDATIONS for BioNTech and WashTec shares!
Market leadership, increased efficiency, dividends, and share buybacks - all good reasons to buy WashTec shares. Analysts at M.M. Warburg share this assessment. Their earnings estimates for the coming years may even be too conservative. Unfortunately, nothing about BASF is conservative; rather, it is disappointing. The chemical company has once again failed to meet analysts' forecasts. Its strong free cash flow is based on lower investments, which is also not a good sign. How are analysts reacting? BioNTech is facing a groundbreaking year. Analysts see potential for share price growth. News from the bulging product pipeline is likely to have a significant impact on the share price.
Read
Commented by André Will-Laudien on January 19th, 2026 | 07:20 CET
Black Monday: Despite Greenland disputes, tariffs, and Mercosur, biotech is on the rise! Bayer, Vidac Pharma, BioNTech, and Novo Nordisk in focus
The stock market has had a very volatile start to 2026. Now, due to the unresolved Greenland issue, punitive tariffs are even being reintroduced for European countries that wish to stick with the Danish administration. Questions of international law did not impact the stock market in any of the conflicts of 2025. What usually receives a lot of attention, however, are shrinking margins caused by artificial tariffs. Just as the EU had been patting itself on the back over the Mercosur agreement, the next Trump-style threat is looming. The biotech sector is advancing steadily and with considerable momentum. Can the life sciences leaders outperform the DAX?
Read
Commented by Fabian Lorenz on January 7th, 2026 | 07:35 CET
+23% price increase in just a few days! DroneShield, BioNTech, and WashTec shares!
DroneShield shares have already gained over 23% in the first few trading days of the year. The drone defense specialist is receiving a boost from two orders placed shortly before the turn of the year. Is it now heading towards an all-time high? WashTec shares are also performing strongly. While German stocks are weakening overall, WashTec shares are at their highest level in a long time, and analysts see further upside potential. BioNTech has important study data coming up in 2026. But first, the acquisition of CureVac will be completed. This marks the end of a stock market story that caused only brief euphoria.
Read
Commented by Fabian Lorenz on January 2nd, 2026 | 07:10 CET
BYD vs. Tesla! AI beneficiaries BioNTech and Rio Tinto partner Aspermont! Stocks for 2026?
A bombshell just before New Year's Eve! BYD has knocked Tesla off its electric vehicle throne. The Chinese company is now also the global market leader in purely electric vehicles. However, the stock clearly disappointed in 2025. One potential winner in 2026 could be Aspermont shares. The Company combines the booming commodities sector with a scalable technology business model in what is likely a unique way. The stock appears anything but expensive. BioNTech shareholders, on the other hand, had little to cheer about in 2025, as the stock lost almost 30% of its value. However, important study data is due in the current year. Analysts see a buying opportunity.
Read
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read
Commented by Fabian Lorenz on November 5th, 2025 | 07:10 CET
Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?
NetraMark scores again. The Company's AI has convinced yet another biopharma company and is increasingly shaping up as a potential takeover target. The new client will use NetraAI to optimize its clinical trial, cutting both time and costs. The high expense of drug development is clear: BioNTech invested EUR 565 million into its pipeline last quarter. However, the German biotech leader can afford this thanks to billions in its coffers. Analysts still recommend buying the stock. By contrast, even a million-dollar payment from a partner could not give Evotec shares any real momentum. Could today’s figures finally spark a turnaround?
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read